Baxter buys Swedish Gambro
Enlarge image


Baxter buys Swedish Gambro

05.12.2012 - Baxter International Inc. strengthens its dialysis business with the acquisition of Swedish Gambro AB.

Private equity investors sold the firm for about US-$4bn. Gambro has a product portfolio in global home dialysis. The acquisition positions Baxter as the worldwide number two in the dialysis market. The Swedish firm had about US$1.6bn in sales last year. Gambro is owned by Sweden’s EQT Partners AB and Investor AB which is the investment firm controlled by Sweden’s billionaire Wallenberg family.

According to sources, the negotiations started as early as one year ago.Matt Miksic, analyst with Piper Jaffray, welcomed the acquisition in a telephone interview with Bloomberg. “Baxter's renal division is a little bit undersized relative to some of their other businesses; this balances that a bit and gives it a little more weight.” “Both companies have a longstanding heritage in kidney care with innovative technologies and a dedication to saving, sustaining and improving the lives of patients worldwide,” said Guido Oelkers, president and chief executive officer of Gambro.

According to Baxter dialysis is a market that grows by more than 5% per year. The Gambro deal is a further step in the consolidation of the kidney dialysis market, where Gambro and Baxter compete against companies including U.S.-based DaVita HealthCare Partners Inc and Germany's Fresenius Medical Care AG. Baxter manufactures kidney dialysis equipment, drug infusion pumps and blood therapy products. The Gambro acquisition will round out Baxter's renal business, which accounted for almost one-fifth of the company's 2011 revenue of US-$13.89bn.



24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.05 CHF25.00%
  • MOLOGEN (D)4.10 EUR13.89%


  • DIAMYD MEDICAL -B- (S)8.75 SEK-5.91%
  • IMMUNICUM AB (S)40.60 SEK-5.80%
  • CELLECTIS (F)29.57 EUR-5.07%


  • PLETHORA (UK)5.50 GBP76.3%
  • PROTHENA PLC (IE)73.20 USD46.1%
  • CELLECTIS (F)29.57 EUR27.9%


  • EPIGENOMICS (D)1.84 EUR-59.3%
  • EVOCUTIS (UK)0.10 GBP-33.3%


  • KARO BIO (S)37.50 SEK5181.7%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)44.82 EUR249.1%


  • BIOTEST (D)15.03 EUR-81.4%
  • NEOVACS (F)0.72 EUR-79.1%

No liability assumed, Date: 25.11.2015